Takeda Reacquires Rights to Leading Diabetes Drug in Canada

Takeda Reacquires Rights to Leading Diabetes Drug in Canada

MISSISSAUGA, ON, Aug. 21 /CNW/ - Takeda Canada, Inc. announced that it has reacquired the Canadian commercial rights to ACTOS(R) (pioglitazone HCl), an oral treatment for type 2 diabetes, from Eli Lilly Canada Inc. Takeda, the discoverer of ACTOS, licensed the drug to Lilly as part of a worldwide agreement in 1999.

"Reacquiring the commercial rights to ACTOS is Takeda's first opportunity to establish a commercial presence in Canada," said Daaron Dohler, general manager at Takeda Canada. "It also underscores Takeda's ongoing efforts to reinforce our global operations and build a stronger presence in North America."

ACTOS was approved by Health Canada as monotherapy to decrease insulin resistance and blood glucose levels in patients with type 2 diabetes mellitus, in September 2000. Takeda has taken over responsibility for ACTOS in the Canadian market effective mid-June. The company already sells ACTOS in many other territories, including the United States, Japan and most of Europe.

About Takeda Canada, Inc.

Based in Mississauga, Ontario, Takeda Canada, Inc. is a subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The company currently markets an oral diabetes treatment, and seeks to bring innovative products to patients through a pipeline that includes compounds in development for diabetes, cardiovascular disease, oncology, gastroenterology, rheumatology and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda Canada is available through its web site, www.takedacanada.com.

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.